KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-versus- host disease in haploidentical transplantation.

Zheng-Li Xu, Ting-Ting Han, Xiao-Lu Zhu, Jing Liu, Meng Lv, Yu-Qian Sun, Xiao-Dong Mo, Yi-Fei Cheng, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yu Wang

Haematologica 110(12) 2965-2973

PMID40534493
PMCIDPMC12666268
DOI10.3324/haematol.2025.287504
发表日期2025-06-19
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

The combination of anti-thymocyte globulin (ATG) and posttransplant cyclophosphamide (PTCy) appears to be a potentially effective graft-versus-host disease (GVHD) prevention strategy for haploidentical transplantation. However, the majority of the evidence originated from retrospective studies without uniform protocols. Our previous findings indicated that 10 mg/kg ATG plus low-dose PTCy could decrease GVHD among high-risk populations transplanted from maternal or collateral relatives. We designed an open-label, phase III, randomized controlled trial to compare patients receiving granulocyte colony-stimulating factor (G-CSF)/ATG-based haploidentical transplantation with or without low-dose PTCy (14.5 mg/kg on days 3 and 4) in non-maternal, non-collateral haploidentical transplants from fathers, children or siblings. A total of 66 patients were randomly assigned to ATG-PTCy (N=44) or ATG (N=22) when the first interim analysis was performed. The interim analysis revealed that the 100-day cumulative incidences of grade 2-4 (18.2%, 95% confidence interval [CI]: 6.6-29.7 vs. 18.2%, 95% CI: 1.7-34.7; P=0.996) and 3-4 acute GVHD (2.3%, 95% CI: 0-6.7 vs. 0; P=0.480) were comparable between the ATG-PTCy and ATG cohorts, as was chronic GVHD at 1 year. The estimated 1-year disease-free survival (DFS) rates were also similar between ATG-PTCy and ATG cohorts (95.5%, 95% CI: 89.5-100 vs. 95.2%, 95% CI: 86.6-100; P=0.979). These results suggested that ATG/PTCy (low-dose) had no advantage over 10 mg/kg ATG-based prophylaxis in patients with haploidentical transplantation other than that of maternal donors or collateral relatives. Future work needs to focus on identifying which populations might benefit from the combined strategy in the context of G-CSF/ATG-based protocols (clinicaltrials gov. Identifier: NCT06108739).

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 5

Figure 5. The survival outcomes between ATG-PTCy and ATG groups. The estimated rates of (A) overall survival (OS) and (B) disease-free survival (DFS). allo-HSCT: allogeneic hematopoietic stem cell transplantation; ATG: anti-thymocyte globulin; PTCy: posttransplant cyclophosphamide.

A

OS

Figure 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:flat topline artifact曲线 2:extreme upward reversal
查看结果
B

DFS

Figure 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. The cumulative incidence of engraftment between ATG-PTCy and ATG groups. (A) The cumulative incidence of neutrophil engraftment and (B) platelet engraftment. allo-HSCT: allogeneic hematopoietic stem cell transplantation; ATG: anti-thymocyte globulin; PTCy: posttransplant cyclophosphamide.
非 KM Figure
Figure 2Figure 2. The 100-day cumulative incidences of acute graft- versus -host disease between ATG-PTCy and ATG groups. (A) The 100-day cumulative incidences of grade 2-4 and (B) grade 3-4 acute graft- versus -host disease (GVHD). allo-HSCT: allogeneic hematopoietic stem cell transplantation; ATG: anti-thymocyte globulin; PTCy: posttransplant cyclophosphamide.
非 KM Figure
Figure 3Figure 3. The cumulative incidences of chronic acute graft- versus -host disease between ATG-PTCy and ATG groups. (A) The cumulative incidences of chronic graft- versus -host disease (GVHD) and (B) moderate to severe chronic GVHD. allo-HSCT: allogeneic hematopoietic stem cell transplantation; ATG: anti-thymocyte globulin; PTCy: posttransplant cyclophosphamide.
非 KM Figure
Figure 4Figure 4. The comparisons of relapse and transplantation-related mortality between ATG-PTCy and ATG groups. (A) The cumulative incidence of relapse and (B) transplantation-related mortality (TRM). allo-HSCT: allogeneic hematopoietic stem cell transplantation; ATG: anti-thymocyte globulin; PTCy: posttransplant cyclophosphamide.
非 KM Figure